398

4454228

PATENT ABSTRACTS

B I O L O G I C A L L Y P U R E C U L T U R E O F S T R E P T O M Y C E S

M I C R O S P I N U S N R R L 12524 C A P A B L E O F P R O D U C I N G

A N T I B I O T I C U-64 ,815

Howard A Whaley. William C Snyder, John C Greenfield, John H Coats assigned to The Up- john Company

Novel antibiotic U-64,815 producible in a fer- mentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces microspinus, NRRL 12524. This antibiotic is active against various Gram- positive bacteria, for example, Staphylococcus aureus. It is also active against Haemophilus in- fluenzae. Thus. antibiotic U-64.815 can be used in various environments to eradicate or control such bacteria.

4455296

H Y B R I D C E L L L I N E S P R O D U C I N G M O N O C L O N A L

A N T I B O D I E S D I R E C T E D A G A I N S T H A E M O P H I L U S

I N F L U E N Z A E

Eric J Hansen, John R Kettman. Stella M Robertson assigned to Board of Regents the University of Texas System

Continuous hybrid cell hnes for producing monoclonal antibodies directed against outer membrane antigens of Haemophilus influenzae type b have been developed. The hybrid cell lines were established by fusing differentiated lymphoid cells primed with outer membrane antigens of Haemophilus influenzae type b with hybridoma cells. The resulting fused cells were cloned and characterized as to antibody specificity against antigenic determinants of outer membranes of Haemophilus influenzae type b. One hybrid produces a monoclonal anti- body which is capable of conferring passive im- munity on Hib infected hosts.

4455290

I N H I B I T I O N O F F I B R I N P O L Y M E R I Z A T I O N BY A

P E P T I D E I S O L A T E D F R O M F I B R I N F R A G M E N T D1

Stephanie A Olexa, Andrei Z Budzynski as- signed to Research Corporation

A purified peptide isolated from fibrinogen Fragment DI and having the amino acid sequence Thr-Arg-Trp-Tyr-Ser-Met-Lys- Lys- Thr-Thr-Met-Lys-Ile-Ile-Pro-Phe-Asn-Arg-Le u-Thr- lle-Gly-Glu-Gly-Gln-Gln-His-His- Leu- Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp- Val. The peptide is isloated by degrading Fragment D l of fibrinogen with plasmin followed by separation of the resulting peptides on the basis of molecular weight and affinity for bound fibrin monomer. The purified peptide is useful as an anticoagulant and, when suitably labeled with a gamma-emitting radioisotope, as a thrombus imaging agent.

4455297

M E T H O D F O R P R O D U C I N G P E R T U S S I S T O X O I D

Yukio Syukuda, Hideo Watanabe. Shigeo Mat- suyama, Hikari, Japan assigned to Takeda Chemical Industries Ltd

A pertussis toxoid is produced by removing endotoxin from a culture supernatant of a Bordetella pertussis phase I strain or a concen- trate thereof and flocculating pertussis exotoxin in the resultant fluid by permitting formaldehyde to act upon the fluid in the substantial absence of basic amino acid. The thus-obtained pertussis toxoid is low in toxicity and has a high im- munizing potency.

4455301

A N T I H E M O P H I L I C F A C T O R C O N C E N T R A T E

Gauta Mitra, John Lundblad assigned to Cutter Laboratories Inc